Nutritive value of Tanzania grass for dairy cows under rotational grazing

A nutritional analysis of Tanzania grass (Megathyrsus maximus Jacquin cv. Tanzânia was conducted. Pasture was managed in a rotational grazing system with a 30-day resting period, three days of paddock occupation and two grazing cycles. Ten Holstein × Zebu crossbred cows were kept within a 2-ha area divided into 11 paddocks ha-1. Cows were fed 2 kg of corn meal daily and performance was evaluated by weighing the animals every 14 days and by recording milk production twice a day. Nutritional composition of the Tanzania grass was determined from forage (extrusa) samples collected by esophageal fistulae from two animals. The nutritive value of Tanzania grass was estimated according to a modification of the CNCPS evaluation model. Tanzania grass supplemented with 2 kg of corn meal supplied 33.2% more net energy for lactation than required by the animals to produce 13.7 kg of milk day-1. Nevertheless, the amount of metabolizable protein met the daily protein requirement of the animals. Although the model used in the study requires adjustments, Tanzania grass has the potential to produce milk in a rotational grazing system

Acetonic Extract of Buxus sempervirens Induces Cell Cycle Arrest, Apoptosis and Autophagy in Breast Cancer Cells

Plants are an invaluable source of potential new anti-cancer drugs. Here, we investigated the cytotoxic activity of the acetonic extract of Buxus sempervirens on five breast cancer cell lines, MCF7, MCF10CA1a and T47D, three aggressive triple positive breast cancer cell lines, and BT-20 and MDA-MB-435, which are triple negative breast cancer cell lines. As a control, MCF10A, a spontaneously immortalized but non-tumoral cell line has been used. The acetonic extract of Buxus sempervirens showed cytotoxic activity towards all the five studied breast cancer cell lines with an IC50 ranging from 7.74 µg/ml to 12.5 µg/ml. Most importantly, the plant extract was less toxic towards MCF10A with an IC50 of 19.24 µg/ml. Fluorescence-activated cell sorting (FACS) analysis showed that the plant extract induced cell death and cell cycle arrest in G0/G1 phase in MCF7, T47D, MCF10CA1a and BT-20 cell lines, concomitant to cyclin D1 downregulation. Application of MCF7 and MCF10CA1a respective IC50 did not show such effects on the control cell line MCF10A. Propidium iodide/Annexin V double staining revealed a pre-apoptotic cell population with extract-treated MCF10CA1a, T47D and BT-20 cells. Transmission electron microscopy analyses indicated the occurrence of autophagy in MCF7 and MCF10CA1a cell lines. Immunofluorescence and Western blot assays confirmed the processing of microtubule-associated protein LC3 in the treated cancer cells. Moreover, we have demonstrated the upregulation of Beclin-1 in these cell lines and downregulation of Survivin and p21. Also, Caspase-3 detection in treated BT-20 and T47D confirmed the occurrence of apoptosis in these cells. Our findings indicate that Buxus sempervirens extract exhibit promising anti-cancer activity by triggering both autophagic cell death and apoptosis, suggesting that this plant may contain potential anti-cancer agents for single or combinatory cancer therapy against breast cancer

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Thigh-length compression stockings and DVT after stroke

Controversy exists as to whether neoadjuvant chemotherapy improves survival in patients with invasive bladder cancer, despite randomised controlled trials of more than 3000 patients. We undertook a systematic review and meta-analysis to assess the effect of such treatment on survival in patients with this disease

Efeitos da adição de propilenoglicol ou monensina à silagem de milho sobre a cinética de degradação dos carboidratos e produção cumulativa de gases in vitro Effects of adding propylene glycol or monensin to corn silage on the degradation kinetics of carbohydrates and in vitro cumulative gas production

Avaliaram-se os efeitos dos aditivos propilenoglicol e/ou monensina sobre a degradabilidade média e efetiva dos carboidratos totais, pH e produção cumulativa de gases da silagem de milho por meio da técnica in vitro semi-automática de produção de gases. Os tratamentos constituíram-se de silagem de milho (SM); SM associada ao propilenoglicol (SM+PG); SM associada à monensina (SM+MO); SM associada ao propilenoglicol e à monensina (SM+PG+MO) avaliados com duas, quatro, seis, 12, 24, 48 e 96 horas. A adição de monensina ou monensina associada ao propilenoglicol aumentou (P<0,05) a degradabilidade dos carboidratos totais às duas horas. SM+MO apresentou maior degradabilidade efetiva dos carboidratos totais em todas as taxas de passagem. A utilização de monensina reduziu a produção cumulativa de gases das 12 às 96 horas. Entre os tratamentos, SM+MO apresentou o menor potencial de produção de gases (221ml/g carboidratos totais) e o menor tempo de colonização (1,08 horas) em relação aos tratamentos SM e SM+PG (1,58 e 1,49 horas, respectivamente). A produção cumulativa de gases e degradabilidade dos carboidratos totais apresentaram elevada correlação, variando de 94 a 97% (P<0,01). O pH do meio foi inversamente correlacionado à degradabilidade dos carboidratos totais (r= -79%, P<0,01). O uso de monensina pode ser uma boa alternativa para se melhorarem os parâmetros da cinética de degradação da silagem de milho.<br>The effects of the additives propylene glycol and/or monensin on the degradation of total carbohydrates, pH, and cumulative gas production of corn silage by the semi-automated in vitro gas production technique were evaluated. The treatments were corn silage (CS); CS plus propylene glycol (CS+PG); CS plus monensin (CS+MO), and CS plus propylene glycol and monensin (CS+PG+MO), which were evaluated at two, four, six, 12, 24, 48, and 96 hours. The addition of monensin or monensin plus propylene glycol increased (P<0.05) the degradation of total carbohydrates at 2h. The effective degradations of total carbohydrates for CS+MO treatment (55.2; 42.7; and 36.5%) were the highest in all passage rates. The use of monensin reduced cumulative gas production from 12 to 96h. CS+MO treatment had the lowest potential of gas production (221ml/g total carbohydrates), and the lowest Lag phase (1.08h), as compared to CS and CS+PG treatment (1.58 and 1.49h, respectively). Cumulative gas production and degradation of total carbohydrates were highly correlated (94 to 97%; P<0.01). The pH was inversely correlated to degradability of total carbohydrates (r= -0.79; P<0.01). Thus, monensin may be used for improving the ruminal degradability of corn silage